Skip to content

Government5 min read

FDA Approves Bemotrizinol: First New U.S. Sunscreen Ingredient

The FDA approved bemotrizinol, the first new sunscreen active ingredient in the U.S. in decades. Get details on this broad-spectrum filter, PARSOL Shield, and its impact.

Share

Topics

Exterior sign for the U.S. Department of Health and Human Services, Food and Drug Administration, with the agency seals on the left.

FDA approves bemotrizinol as first new US sunscreen filter in decades; PARSOL Shield sunscreen expected in 2026

The FDA on June 9, 2026 approved bemotrizinol as a new OTC sunscreen active ingredient, marking the first U.S. sunscreen filter addition in over 25 years and promising broader, photostable UV protection under the trade name PARSOL Shield.

  • FDA permits bemotrizinol (BEMT) up to 6% and finds it GRASE for ages 6 months and older — see the FDA press release.
  • DSM will market the ingredient in the U.S. as PARSOL Shield, with launches expected later in 2026 and an ~18‑month exclusivity window for DSM. See trade analysis and industry reporting.
  • The approval used the OMOR pathway under the CARES Act, signaling faster reviews for future filters — see the FDA Q&A.

What the FDA did and why it matters

On June 9, 2026, the FDA issued a final administrative order adding bemotrizinol to the OTC sunscreen monograph (M020), making it a permitted active ingredient for nonprescription sunscreens in the United States. The final order follows a proposed administrative order issued in December 2025 and a public comment period that closed in January 2026 — details in the proposed order and the final order.

“The agency historically moved too slowly in this area,” Commissioner Marty Makary, MD, MPH said, and FDA officials framed this as a step toward modernizing U.S. sunscreen regulation. Karen Murry, MD, called bemotrizinol “a welcome addition.”

How bemotrizinol got approved

DSM Nutritional Products LLC submitted an OTC Monograph Order Request (OMOR) on Sept. 23, 2024 seeking approval to use bemotrizinol up to 6% in OTC sunscreens. The OMOR process, part of CARES Act reforms, allows addition of actives without the older rulemaking process. After review of safety and performance data and public comments, the FDA concluded bemotrizinol is “generally recognized as safe and effective” (GRASE) for adults and children 6 months and older. See the FDA press release and FDA Q&A for submission and process details.

What bemotrizinol is and how it works

Bemotrizinol (BEMT) is a modern organic UV filter widely used overseas. It provides broad‑spectrum UVA and UVB protection, is highly photostable, and blends well with other filters and bases to enable lighter, cosmetically elegant sunscreens — features that can improve user compliance. See the scientific review and related product notes.

Safety, absorption and testing data

The FDA’s GRASE finding relied on clinical pharmacokinetic, irritation and performance studies. A key pharmacokinetic study found plasma concentrations rarely exceeded 0.5 ng/mL, a low level consistent with FDA safety benchmarks. Irritation and sensitization studies reported few adverse effects and mostly mild skin reactions. The agency concluded bemotrizinol is safe for the approved concentration and age ranges — see the FDA review and the scientific study summary.

Conditions of use in U.S. sunscreens

The final order permits bemotrizinol at up to 6% in common topical forms—lotions, creams, oils, gels, sticks and many spray formats (with limits for propellant sprays). Products must meet all monograph requirements, including SPF and broad‑spectrum testing, Drug Facts labeling, establishment registration and drug listing before distribution. Allowing bemotrizinol does not waive monograph obligations; manufacturers must fully comply to avoid misbranding or unapproved product status. See regulatory guidance.

Timing, exclusivity and PARSOL Shield

DSM will market bemotrizinol in the U.S. under the trade name PARSOL Shield. Industry reports indicate DSM expects product launches later in 2026, after formulation testing, labeling and supply‑chain steps. Under OMOR rules, DSM may receive an approximately 18‑month exclusivity based on its data submission; during that period, other manufacturers cannot rely on DSM’s data package but may pursue independent pathways. After exclusivity ends, broader adoption is expected. See trade analysis and the industry report.

How the U.S. compares with the rest of the world

Bemotrizinol has been used for years overseas and is permitted at higher concentrations in some markets (often up to 10% in parts of Europe and Asia), while Canada uses a 6% limit that the U.S. now matches. Many experts say the U.S. gap reflected regulatory bottlenecks rather than unresolved safety problems. This decision narrows that gap and aligns U.S. practice more closely with global markets. See the international scientific review.

Why this could be a turning point

This approval is viewed as a test case for the OMOR pathway, created after the CARES Act and reinforced by policy efforts such as the SAFE Sunscreen Standards Act. A successful OMOR for bemotrizinol may encourage additional submissions for newer filters, speeding consumer access to modern sunscreen chemistry in the U.S. See industry analysis at HK Law and the FDA Q&A.

What this means for consumers

When PARSOL Shield–containing sunscreens reach store shelves, shoppers can expect options that may offer stronger, longer‑lasting UVA protection and lighter, more cosmetically pleasing textures — features that can encourage more regular use. However, core sun‑safety advice remains unchanged: use broad‑spectrum SPF 15 or higher, reapply regularly, wear protective clothing and limit time in peak sun. The FDA reiterates that sunscreen is one part of a broader sun‑safety routine; see the FDA press release.

Implications for Los Angeles, California

  • Public health and skin cancer prevention: LA residents face year‑round strong UV exposure. A photostable filter like bemotrizinol could improve protection for outdoor workers, beachgoers and children and help reduce sunburn and long‑term skin damage when combined with standard precautions (see the scientific review).
  • Consumer choice and compliance: Cosmetics‑minded consumers in Los Angeles often prioritize feel and appearance. PARSOL Shield formulations promising lighter, non‑greasy finishes may increase everyday sunscreen use (see product notes).
  • Local businesses and manufacturers: California brands and retailers will watch the 18‑month exclusivity window closely; after it lapses, local manufacturers may introduce bemotrizinol‑based lines (see trade analysis).
  • Occupational exposure and regulations: Employers with outdoor workers may have new product options for workplace sun‑safety programs, but procurement must ensure products comply with FDA monograph conditions and labeling.
  • Equity and access concerns: New filters can be costlier at first. Public health officials and community organizations should monitor availability and pricing to ensure access for lower‑income residents.

Reporting and sources

This article draws on FDA announcements, regulatory analysis, scientific literature and industry reporting. Key sources include the FDA press release, the FDA proposed order, the FDA Q&A, the scientific review, trade and legal analysis at Diaz Trade Law and HK Law, and industry coverage at HealthCentral.

Share

Topics

Kevin Morgan

Kevin Morgan is a senior food and dining writer for Times Media Service, based in Los Angeles, California. Morgan covers food and dining, along with sports and health, bringing an evidence-based, community-focused approach to health reporting. Morgan holds a master's degree in sport administration and grew up in Canton, Ohio.

Write to Kevin